Improving lung cancer survival; time to move on

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Heuvers, Marlies E ^a   Hegmans, Joost P ^a   Stricker, Bruno H ^a   Aerts, Joachim G ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

Immunotherapy; Lung cancer; Lung cancer screening; Survival

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; IPILIMUMAB; LUNG CANCER VACCINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; TREATMENT RESPONSE;

DRUG THERAPY; EARLY DETECTION OF CANCER; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84870951270     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-77     Document Type: Article

References (42)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236. 10.3322/caac.20121, 21685461.
2. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. 10.1056/NEJMoa011954, 11784875.
3. Sugimura H, Yang P. Long-term survivorship in lung cancer: a review. Chest 2006, 129:1088-1097. 10.1378/chest.129.4.1088, 16608961.
4. Goodgame B, et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009, 4:1370-1374. 10.1097/JTO.0b013e3181b6bc1b, 19692932.
5. Goodgame B, et al. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol 2008, 31:22-28. 10.1097/COC.0b013e3180ca77d1, 18376223.
6. Blanchon T, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007, 58:50-58. 10.1016/j.lungcan.2007.05.009, 17624475.
7. van Klaveren RJ, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009, 361:2221-2229. 10.1056/NEJMoa0906085, 19955524.
8. International Early Lung Cancer Action Program Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-1771. International Early Lung Cancer Action Program.
9. Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K. Screening and early detection of lung cancer. Ann Oncol 2012, 23(Suppl 10):x320-x327. 10.1093/annonc/mds303, 22987984.
10. National Lung Screening Trial Research, T Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409. National Lung Screening Trial Research, T.
11. Heuvers ME, Stricker BH, Aerts JG. Generalizing lung-cancer screening results. N Engl J Med 2012, 366:192-193. 10.1056/NEJMc1111935, 22236243.
12. Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008, 86:2008-2016. discussion 2016-2008, 10.1016/j.athoracsur.2008.07.009, 19022040.
13. Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011, 43:75-82. 10.4143/crt.2011.43.2.75, 3138920, 21811422.
14. Wisnivesky JP, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011, 343:d4013. 10.1136/bmj.d4013, 3136092, 21757436.
15. Heuvers ME, et al. History of tuberculosis as an independent prognostic factor for lung cancer survival. Lung Cancer 2012, 76:452-456. 10.1016/j.lungcan.2011.12.008, 22226628.
16. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011, 60:319-326. 10.1007/s00262-010-0968-0, 3042096, 21267721.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
18. Caux C, Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine?. Target Oncol 2012, 7:1-2.
19. Zitvogel L, et al. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010, 70:9538-9543. 10.1158/0008-5472.CAN-10-1003, 21098713.
20. Keyler DE, et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 2005, 33:1056-1061. 10.1124/dmd.105.004234, 15843487.
21. Jadus MR, et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012, 2012:160724. 3414063, 22899945.
22. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812. 10.1038/nrc3153, 3426440, 22020206.
23. Cornelissen R, et al. New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012, 2012:927240. 3388483, 22778767.
24. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011, 71:1093-1104. 10.2165/11594010-000000000-00000, 21668044.
25. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465. 10.1056/NEJMoa1200694, 22658128.
26. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 22658127.
27. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011, 10:411-412. 10.1038/nrd3463, 21629286.
28. Minchom A, Young K, Larkin J. Ipilimumab: showing survival benefit in metastatic melanoma. Future Oncol 2011, 7:1255-1264. 10.2217/fon.11.105, 22044200.
29. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011, 26:1-64. 10.1089/cbr.2010.0902, 21355777.
30. Claret L, et al. Simulations using a drug-disease modeling framework and phase ii data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther 2012, 92:631-634. 10.1038/clpt.2012.78, 22910440.
31. Manzoni M, et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010, 79:187-196. 10.1159/000320609, 21358206.
32. Osada T, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008, 57:1115-1124. 10.1007/s00262-007-0441-x, 18193223.
33. Winter H, et al. Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011, 3:105-114. 3256502, 22263073.
34. Um SJ, et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer 2010, 70:188-194. 10.1016/j.lungcan.2010.02.006, 20223553.
35. Neninger Vinageras E, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458. 10.1200/JCO.2007.11.5980, 18349395.
36. Barve M, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008, 26:4418-4425. 10.1200/JCO.2008.16.6462, 18802154.
37. Palmer M, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cance. Clin Lung Cancer 2001, 3:49-57. discussion 58, 10.3816/CLC.2001.n.018, 14656392.
38. Hegmans JP, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181:1383-1390. 10.1164/rccm.200909-1465OC, 20167848.
39. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372. 10.1016/j.lungcan.2007.04.002, 2063443, 17509725.
40. Perroud MW, et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 2011, 30:65. 10.1186/1756-9966-30-65, 3135553, 21682877.
41. Iliopoulou EG, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789. 10.1007/s00262-010-0904-3, 20703455.
42. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308. 10.1038/nrc2355, 2553205, 18354418.